欧洲泌尿外科学会非肌层浸润性膀胱癌指南(2021版)
欧洲泌尿外科学会(EAU)发布了2021版非肌层浸润性膀胱癌(NMIBC)指南,涵盖Ta、T1及原位癌(CIS)。诊断依赖膀胱镜及经尿道膀胱肿瘤电切(TURB)或活检的组织学评估,强调完整TURB对预后和正确诊断至关重要。根据2021 EAU评分模型评估进展风险并分层为低、中、高、极高危,以指导辅助治疗。
要点
- 对于初次切除不完整、标本无肌层或检出T1肿瘤,应在2-6周内行第二次TURB。
- 低危肿瘤及上次TURB后1年以上出现的小乳头状复发,推荐一次即刻化疗灌注。
- 中危肿瘤应接受1年足量卡介苗(BCG)膀胱灌注或最多1年化疗灌注。
核心结论
- EAU更新了NMIBC指南,基于截至2020年的文献,强调最高级别证据。
- 根据个体进展风险将患者分为低、中、高或极高危,对辅助治疗决策至关重要。
- 对BCG无反应及进展风险最高的肿瘤应考虑膀胱切除术。
研究设计与样本
- 指南制定机构:欧洲泌尿外科学会(EAU)。
- 证据检索覆盖Medline、EMBASE和Cochrane图书馆,更新自2020版指南。
- 对证据等级和推荐强度进行了分级。
主要发现
- 诊断依赖膀胱镜及经尿道膀胱肿瘤电切(TURB)或多次膀胱活检的组织学评估。
- 对于乳头状病变,完整的TURB对患者预后和正确诊断至关重要。
- 2021 EAU评分模型可用于个体患者进展风险评估。
关键数值与推荐
- 第二次TURB应在2-6周内进行,适用于初次切除不完整、标本无肌层或检出T1肿瘤。
- 低危肿瘤及上次TURB后1年以上出现的小乳头状复发:推荐一次即刻化疗灌注。
- 中危肿瘤:1年足量膀胱内BCG免疫治疗或最多1年化疗灌注。
- 高危肿瘤:1-3年足量膀胱内BCG。
- 极高危肿瘤:考虑即刻根治性膀胱切除术;BCG无反应肿瘤也推荐膀胱切除术。
临床怎么用
- 临床应根据2021 EAU评分模型对NMIBC患者进行进展风险分层。
- 依据风险分层选择辅助治疗方案:低危即刻化疗灌注,中危BCG或化疗1年,高危BCG 1-3年。
- 极高危或BCG无反应患者应考虑根治性膀胱切除术。
局限性
- 指南基于截至2020年的文献,未纳入此后新证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: The European Association of Urology (EAU) has released an updated version of the guidelines on non-muscle-invasive bladder cancer (NMIBC). OBJECTIVE: To present the 2021 EAU guidelines on NMIBC. EVIDENCE ACQUISITION: A broad and comprehensive scoping exercise covering all areas of the NMIBC guidelines since the 2020 version was performed. Databases covered by the search included Medline, EMBASE, and the Cochrane Libraries. Previous guidelines were updated, and the level of evidence and grade of recommendation were assigned. EVIDENCE SYNTHESIS: Tumours staged as Ta, T1 and carcinoma in situ (CIS) are grouped under the heading of NMIBC. Diagnosis depends on cystoscopy and histological evaluation of tissue obtained via transurethral resection of the bladder (TURB) for papillary tumours or via multiple bladder biopsies for CIS. For papillary lesions, a complete TURB is essential for the patient's prognosis and correct diagnosis. In cases for which the initial resection is incomplete, there is no muscle in the specimen, or a T1 tumour is detected, a second TURB should be performed within 2-6 wk. The risk of progression may be estimated for individual patients using the 2021 EAU scoring model. On the basis of their individual risk of progression, patients are stratified as having low, intermediate, high, or very high risk, which is pivotal to recommending adjuvant treatment. For patients with tumours presumed to be at low risk and for small papillary recurrences detected more than 1 yr after a previous TURB, one immediate chemotherapy instillation is recommended. Patients with an intermediate-risk tumour should receive 1 yr of full-dose intravesical bacillus Calmette-Guérin (BCG) immunotherapy or instillations of chemotherapy for a maximum of 1 yr. For patients with high-risk tumours, full-dose intravesical BCG for 1-3 yr is indicated. For patients at very high risk of tumour progression, immediate radical cystectomy should be considered. Cystectomy is also recommended for BCG-unresponsive tumours. The extended version of the guidelines is available on the EAU website at https://uroweb.org/guideline/non-muscle-invasive-bladder-cancer/. CONCLUSIONS: These abridged EAU guidelines present updated information on the diagnosis and treatment of NMIBC for incorporation into clinical practice. PATIENT SUMMARY: The European Association of Urology has released updated guidelines on the classification, risk factors, diagnosis, prognostic factors, and treatment of non-muscle-invasive bladder cancer. The recommendations are based on the literature up to 2020, with emphasis on the highest level of evidence. Classification of patients as having low, intermediate, or and high risk is essential in deciding on suitable treatment. Surgical removal of the bladder should be considered for tumours that do not respond to bacillus Calmette-Guérin (BCG) treatment and tumours with the highest risk of progression.
引用
- Babjuk M, Burger M, Capoun O, et al. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ). Eur Urol. 2021. PMID: 34511303. doi:10.1016/j.eururo.2021.08.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。